Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcello Ceppi

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Carcinogenesis|March 22, 2008
Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countriesStefano Bonassi, Hannu Norppa, Marcello Ceppi, et al.
Cancers|December 22, 2019
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223Matteo Bauckneht, Selene Capitanio, Maria Isabella Donegani, et al.
Mutation Research|September 16, 2009
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolismFederica Gemignani, Monica Neri, Fabio Bottari, et al.
International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
Cancers|August 26, 2022
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-AnalysisValentina Russo, Eleonora Lallo, Armelle Munnia, et al.
NPJ Breast Cancer|June 29, 2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 13, 2016
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studiesMatteo Lambertini, Marcello Ceppi, Francesco Cognetti, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2016
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factorSilvio Roncella, Stefania Laurent, Vincenzo Fontana, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|January 20, 2023
Genotoxic effects of occupational exposure to glass fibres - A human biomonitoring studyMarcello Ceppi, Bozena Smolkova, Marta Staruchova, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Carcinogenesis|March 22, 2008
Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22 358 subjects in 11 countriesStefano Bonassi, Hannu Norppa, Marcello Ceppi, et al.
Cancers|December 22, 2019
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223Matteo Bauckneht, Selene Capitanio, Maria Isabella Donegani, et al.
Mutation Research|September 16, 2009
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolismFederica Gemignani, Monica Neri, Fabio Bottari, et al.
International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
Cancers|August 26, 2022
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-AnalysisValentina Russo, Eleonora Lallo, Armelle Munnia, et al.
NPJ Breast Cancer|June 29, 2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 13, 2016
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studiesMatteo Lambertini, Marcello Ceppi, Francesco Cognetti, et al.
Cancer Immunology, Immunotherapy : CII|May 22, 2016
CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factorSilvio Roncella, Stefania Laurent, Vincenzo Fontana, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|January 20, 2023
Genotoxic effects of occupational exposure to glass fibres - A human biomonitoring studyMarcello Ceppi, Bozena Smolkova, Marta Staruchova, et al.
Pageof 13